CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 540 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Cor e Forma:LiquidKinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Cor e Forma:Odour SolidRef: TM-L1600
1mgA consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarEGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Fórmula:C30H20N6OSPureza:98%Cor e Forma:SolidPeso molecular:512.58PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Fórmula:C44H52Cl2N10O7Pureza:98%Cor e Forma:SolidPeso molecular:903.85HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Fórmula:C28H29Cl2F3N4O4Cor e Forma:SolidPeso molecular:613.46CDK8-IN-12
CAS:CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.Fórmula:C21H20ClN3O2Pureza:98.55% - 99.22%Cor e Forma:SoildPeso molecular:381.86Ref: TM-T72048
1mg52,00€5mg101,00€10mg150,00€25mg250,00€50mg363,00€100mg509,00€200mg695,00€1mL*10mM (DMSO)116,00€CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.
Cor e Forma:Odour SolidPROTAC CDK9 degrader-7
CAS:PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (Fórmula:C43H50Cl2N8O9Cor e Forma:SoildPeso molecular:893.81SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Fórmula:C15H14N2OPureza:99.96%Cor e Forma:SolidPeso molecular:238.28NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Fórmula:C40H29ClIrN5OCor e Forma:SolidPeso molecular:823.36PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Fórmula:C43H51FN12O7Cor e Forma:SolidPeso molecular:866.94CDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Fórmula:C20H21F2N9Cor e Forma:SolidPeso molecular:425.448Cdk2/Cyclin Inhibitory Peptide I
CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.Fórmula:C111H196N48O23Pureza:98%Cor e Forma:SolidPeso molecular:2571.05CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Fórmula:C38H42N12O10S2Cor e Forma:SolidPeso molecular:890.94CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Fórmula:C34H45N9O2Cor e Forma:SolidPeso molecular:611.795PROTAC CDK9 degrader-2
CAS:PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.Fórmula:C39H36N6O10Pureza:98%Cor e Forma:SolidPeso molecular:748.74PROTAC CDK9 degrader-5
CAS:PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.Fórmula:C42H48Cl2N8O9Pureza:98%Cor e Forma:SolidPeso molecular:879.78TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Fórmula:C24H16N6OS2Pureza:98%Cor e Forma:SolidPeso molecular:468.55BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Fórmula:C43H48N10O8Cor e Forma:SolidPeso molecular:832.9
